In addition, PNPLA3 I148M and TM6SF2 E167K possess the joint correlation with the decreased risk of CHD in NAFLD patients with the increased number of risk alleles. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.